Home / Market News / $AXSM
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Analysts Adjust Price Targets for Axsome Therapeutics Following Q3 Results

Nov 3, 2026, 11:05 PM UTC · Primary ticker $AXSM

Following Axsome Therapeutics' Q3 2026 earnings, multiple analysts, including Baird and Bank of America, lowered their price targets for the company's stock. These adjustments, while generally maintaining positive ratings, reflect concerns over the adoption rate of their Alzheimer's treatment and overall commercial execution, indicating a moderate negative sentiment shift.

Axsome Therapeutics experienced a wave of analyst price target reductions following its Q3 2026 earnings release. While most firms, including Baird and BofA, maintained 'Outperform' or 'Buy' ratings, the lowered targets signal investor and analyst concerns, particularly regarding the slower-than-expected adoption of the company's Alzheimer's agitation treatment. This indicates a short-term headwind for the stock as the market digests these revised expectations and commercial execution challenges. The long-term outlook, however, remains generally positive according to these analysts, suggesting that the current adjustments are more about the pace of growth rather than a fundamental flaw in the company's prospects. For traders, this presents a potential opportunity to monitor for signs of improved commercial execution or a re-acceleration in treatment adoption, which could lead to upward revisions in the future, or a risk if adoption continues to lag.

$AXSM negative Analyst price target reductions
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.